2025
Exploring dopamine as the master regulator of brain circuitry and mental health genome
Blum K, Braverman E, Sharafshah A, Elman I, Lewandrowski K, Bowirrat A, Pinhasov A, Thanos P, Gold M, Dennen C, Modestino E, Badgaiyan R, Baron D, Fuehrlein B, Sipple D, Ashford J, Sunder K, Makale M, Murphy K, Jafari N, Zeine F, Pollack A, Lewandowski P, Khalsa J. Exploring dopamine as the master regulator of brain circuitry and mental health genome. Gene & Protein In Disease 2025, 0: 6557. DOI: 10.36922/gpd.6557.Peer-Reviewed Original ResearchBrain circuitryDopamine transmissionDopaminergic activityPsychiatric disordersDopamineBrain functionCircuitryLong-term influenceNeurobiologyAddictionImmediate effectsIntracellular signaling pathwaysPotential therapeutic targetDisordersNeurotransmitterBrainClinical relevanceTherapeutic targetSignaling pathwaySubstances
2024
Novel multi-modal methodology to investigate placebo response in major depressive disorder
Cusin C, Dillon D, Belleau E, Normandin M, Petibon Y, El-Fakri G, Dhaynaut M, Hooker J, Kaptchuk T, McKee M, Hayden E, Meyer A, Jahan A, Origlio J, Ang Y, Brunner D, Kang M, Long Y, Fava M, Pizzagalli D. Novel multi-modal methodology to investigate placebo response in major depressive disorder. Journal Of Affective Disorders 2024, 368: 1-7. PMID: 39233242, DOI: 10.1016/j.jad.2024.08.226.Peer-Reviewed Original ResearchPlacebo responseDepressive disorderRates of placebo responseMesocorticolimbic dopaminergic pathwayExpectation of rewardAntidepressant responseMesolimbic systemReward circuitryNeurobiological underpinningsNeurobiological mechanismsDopaminergic activityDopaminergic systemPlacebo respondersSymptom reductionDopaminergic pathwaysMulti-modal methodologyPlacebo phenomenonPsychological constructsTreatment developmentMDDPlacebo-ControlledClinical trialsDouble-blindRewardDesigning Clinical Trials
2022
Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers
Droby A, Artzi M, Lerman H, Hutchison R, Bashat D, Omer N, Gurevich T, Orr-Urtreger A, Cohen B, Cedarbaum J, Sapir E, Giladi N, Mirelman A, Thaler A. Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers. Npj Parkinson's Disease 2022, 8: 20. PMID: 35241697, PMCID: PMC8894349, DOI: 10.1038/s41531-022-00285-z.Peer-Reviewed Original ResearchStriatal binding ratiosGBA-NMCFunctional connectivity patternsDopamine transporterHealthy first-degree relativesNigrostriatal dopaminergic activityGBA mutation carriersStriatal dopamine uptakeRs-fMRI scansFirst-degree relativesPre-clinical stageResting-state fMRIClinical assessment batteryConnectivity patternsPD patientsDopaminergic deficiencyDopaminergic activityRight putamenMutation carriersStudy groupClinical measuresStriatal regionsParkinson's diseaseDopamine uptakeFunctional alterationsA multi-pronged investigation of option generation using depression, PET and modafinil
Ang Y, Cusin C, Petibon Y, Dillon D, Breiger M, Belleau E, Normandin M, Schroder H, Boyden S, Hayden E, Levine M, Jahan A, Meyer A, Kang M, Brunner D, Gelda S, Hooker J, Fakhri G, Fava M, Pizzagalli D. A multi-pronged investigation of option generation using depression, PET and modafinil. Brain 2022, 145: 1854-1865. PMID: 35150243, PMCID: PMC9166534, DOI: 10.1093/brain/awab429.Peer-Reviewed Original ResearchConceptsD2/D3 receptor availabilitySelf-generated optionsDepressive disorderDepressed individualsReceptor availabilityDopamine D2/D3 receptor availabilityNon-depressed adultsEffects of modafinilPutamen of patientsAssociated with uniquenessOption generationD2/D3 receptorsDopaminergic activityClinical depressionBinding potentialModafinilHealthy participantsPutamenPlacebo-ControlledSamples of healthy peopleDouble-blindDisordersSelf-generationHealthy controlsDopamine
2018
Higher schizotypy predicts better metabolic profile in unaffected siblings of patients with schizophrenia
Atbasoglu E, Gumus-Akay G, Guloksuz S, Saka M, Ucok A, Alptekin K, Gullu S, van Os J. Higher schizotypy predicts better metabolic profile in unaffected siblings of patients with schizophrenia. Psychopharmacology 2018, 235: 1029-1039. PMID: 29306964, DOI: 10.1007/s00213-017-4818-z.Peer-Reviewed Original ResearchConceptsInsulin resistanceDopaminergic activityMetabolic profileHomeostatic model assessmentHDL-C levelsBetter metabolic profilesFavorable metabolic profilePancreatic insulin secretionUnaffected siblingsBeads taskResultsInsulin resistanceTertile groupRegression modelsCentral actionInsulin secretionGeneral populationGenetic predispositionGlucose metabolismModel assessmentSZ patientsRegulatory roleDirect actionSignificant predictorsHigher likelihoodLongitudinal study
2014
Renalase regulates peripheral and central dopaminergic activities
Quelhas-Santos J, Serrão MP, Soares-Silva I, Fernandes-Cerqueira C, Simões-Silva L, Pinho MJ, Remião F, Sampaio-Maia B, Desir GV, Pestana M. Renalase regulates peripheral and central dopaminergic activities. American Journal Of Physiology. Renal Physiology 2014, 308: f84-f91. PMID: 25411385, PMCID: PMC4338928, DOI: 10.1152/ajprenal.00274.2014.Peer-Reviewed Original ResearchConceptsKO miceUrinary excretionPlasma levelsDopaminergic activityIncreased Plasma LevelsPeripheral dopaminergic activityUrine catecholamine levelsRenal dopaminergic systemCentral dopaminergic activityL-type amino acid transporterWild-type miceAmino acid decarboxylase activityKnockout mouse modelRenalase deficiencyCatecholamine levelsDA outputUrinary dopamineAADC activityDopaminergic systemRenal cortexMouse modelDOPA ratioVivo administrationOverexpression of LAT1Amino acid transporters
2013
Stress as a Common Risk Factor for Obesity and Addiction
Sinha R, Jastreboff AM. Stress as a Common Risk Factor for Obesity and Addiction. Biological Psychiatry 2013, 73: 827-835. PMID: 23541000, PMCID: PMC3658316, DOI: 10.1016/j.biopsych.2013.01.032.BooksConceptsNeurobiology of stressHP foodsIncentive salienceFood motivationIntegrative heuristic modelFood-related motivationDevelopment of addictionBiology of stressNeural mechanismsNeurobiological mechanismsAddiction relapsePalatable foodAddictive drugsAllostatic loadMotivationRisk factorsSalienceHigh levelsNeurobiologyHeuristic modelEnergy homeostasisWeight gainAddictionFuture directionsDopaminergic activity
2002
Neuronal Systems Underlying Behaviors Related to Nicotine Addiction: Neural Circuits and Molecular Genetics
Picciotto MR, Corrigall WA. Neuronal Systems Underlying Behaviors Related to Nicotine Addiction: Neural Circuits and Molecular Genetics. Journal Of Neuroscience 2002, 22: 3338-3341. PMID: 11978809, PMCID: PMC6758396, DOI: 10.1523/jneurosci.22-09-03338.2002.Peer-Reviewed Original ResearchConceptsAction of nicotineNicotine addictionNicotinic acetylcholine receptor subunitsAcetylcholine receptor subunitsStudies of miceSerotonergic nucleiNicotine effectsDopaminergic activityDopaminergic systemNicotine dependenceBrainstem cholinergicNeural circuitsNeuronal systemsReceptor subunitsBehavioral effectsNicotineAddictionRecent studiesNeural systemsInitial observationsCholinergicGABAergicMolecular geneticsMice
2000
TMT, a predator odor, elevates mesoprefrontal dopamine metabolic activity and disrupts short-term working memory in the rat
Morrow B, Roth R, Elsworth J. TMT, a predator odor, elevates mesoprefrontal dopamine metabolic activity and disrupts short-term working memory in the rat. Brain Research Bulletin 2000, 52: 519-523. PMID: 10974491, DOI: 10.1016/s0361-9230(00)00290-2.Peer-Reviewed Original ResearchConceptsMedial prefrontal cortexPrefrontal cortexExploratory behaviorSample taskFamiliar objectsNovel objectsMesoprefrontal dopamine neuronsTrimethylthiazolineMemoryPsychological stressTMT exposureObject recognition methodPredator odorSet of objectsCortexElevated serum corticosteroneDopaminergic inputDopaminergic activityBrief exposureDopaminergic innervationSerum corticosteroneDopamine neuronsDopamine metabolismObjectsRecognition method
1990
L-Deprenyl, Levodopa Pharmacokinetics, and Response Fluctuations in Parkinson's Disease.
Cedarbaum JM, Silvestri M, Clark M, Harts A, Kutt H. L-Deprenyl, Levodopa Pharmacokinetics, and Response Fluctuations in Parkinson's Disease. Clinical Neuropharmacology 1990, 13: 29. PMID: 2106391, DOI: 10.1097/00002826-199002000-00003.Peer-Reviewed Original ResearchConceptsParkinson's diseaseResponse fluctuationsL-deprenylTherapeutic response fluctuationsTotal levodopa doseOpen-label trialPlasma levodopa concentrationsPlasma levodopa levelsEffect of deprenylWeeks of treatmentDaily levodopaLevodopa doseLevodopa pharmacokineticsPeripheral pharmacokineticsAction of MAOLevodopa treatmentMost patientsDOPAC levelsLevodopa levelsDopaminergic activityLevodopa concentrationsMild endDose failureTherapeutic actionPatientsPharmacokinetic and Pharmacodynamic Considerations in Management of Motor Response Fluctuations in Parkinson's Disease
Cedarbaum J. Pharmacokinetic and Pharmacodynamic Considerations in Management of Motor Response Fluctuations in Parkinson's Disease. Neurologic Clinics 1990, 8: 31-49. PMID: 2181267, DOI: 10.1016/s0733-8619(18)30372-4.Peer-Reviewed Original ResearchConceptsMotor response fluctuationsResponse fluctuationsLevodopa-related fluctuationsSynthetic dopamine agonistsPlasma levodopa levelsMajority of patientsPharmacokinetics of levodopaSuch treatment approachesBrain dopaminergic activityLong-term treatmentBrain dopamine levelsRapid systemic clearanceAnti-Parkinson agentsLevodopa levelsDopamine agonistsPharmacodynamic consequencesPharmacodynamic considerationsSystemic clearanceAdvanced PDDopamine levelsDopaminergic activityTherapeutic approachesParkinson's diseaseTreatment approachesGalenic formulation
1986
Does the cholecystokinin antagonist proglumide possess antipsychotic activity?
Innis R, Bunney B, Charney D, Price L, Glazer W, Sternberg D, Rubin A, Heninger G. Does the cholecystokinin antagonist proglumide possess antipsychotic activity? Psychiatry Research 1986, 18: 1-7. PMID: 3737785, DOI: 10.1016/0165-1781(86)90056-9.Peer-Reviewed Original ResearchConceptsPsychosis ratingsPlacebo-controlled studyRole of cholecystokininCentral dopaminergic activityCCK receptor antagonistsPathogenesis of schizophreniaMesocortical neuronsNeuroleptic medicationNeurotransmitter statusReceptor antagonistDopaminergic activityAntipsychotic activitySchizophrenic patientsCholecystokininNegative findingsPreclinical researchProglumidePatientsSchizophreniaPotential reasonsMedicationsPathogenesisAntagonistMidbrainNeuropeptides
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply